U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory AL Amyloidosis

MedGen UID:
1750857
•Concept ID:
C5420548
•
Neoplastic Process

Definition

AL amyloidosis that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory AL Amyloidosis

Professional guidelines

PubMed

Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.
Abdallah M, Sanchorawala V
Am J Med 2022 Apr;135 Suppl 1:S30-S37. Epub 2022 Jan 23 doi: 10.1016/j.amjmed.2022.01.011. PMID: 35081382
Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
Hassan H, Anwer F, Javaid A, Hashmi H
Crit Rev Oncol Hematol 2021 Sep;165:103435. Epub 2021 Jul 31 doi: 10.1016/j.critrevonc.2021.103435. PMID: 34343658
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Smolewski P, Rydygier D
Expert Opin Investig Drugs 2019 May;28(5):421-433. Epub 2019 Apr 13 doi: 10.1080/13543784.2019.1596258. PMID: 30907163

Recent clinical studies

Etiology

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B
Blood 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. PMID: 38096365
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E
Am J Hematol 2023 May;98(5):720-729. Epub 2023 Feb 14 doi: 10.1002/ajh.26866. PMID: 36708469
Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
Hassan H, Anwer F, Javaid A, Hashmi H
Crit Rev Oncol Hematol 2021 Sep;165:103435. Epub 2021 Jul 31 doi: 10.1016/j.critrevonc.2021.103435. PMID: 34343658
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schönland S, Fonseca R, Wong S, Kapoor P
Blood Cancer J 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w. PMID: 33431806Free PMC Article
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC
Eur J Haematol 2021 Feb;106(2):184-195. Epub 2020 Nov 9 doi: 10.1111/ejh.13535. PMID: 33090552

Diagnosis

Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H, Rafae A, Masood A, Wahab A, Sana MK, Ansar I, Neupane K, Umar A, Ehsan A, Hashmi H
Clin Lymphoma Myeloma Leuk 2022 May;22(5):e285-e292. Epub 2021 Nov 1 doi: 10.1016/j.clml.2021.10.014. PMID: 34879994
Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
Hassan H, Anwer F, Javaid A, Hashmi H
Crit Rev Oncol Hematol 2021 Sep;165:103435. Epub 2021 Jul 31 doi: 10.1016/j.critrevonc.2021.103435. PMID: 34343658
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC
Eur J Haematol 2021 Feb;106(2):184-195. Epub 2020 Nov 9 doi: 10.1111/ejh.13535. PMID: 33090552
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B
Hematol Oncol 2019 Dec;37(5):595-600. Epub 2019 Nov 6 doi: 10.1002/hon.2677. PMID: 31486522
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Smolewski P, Rydygier D
Expert Opin Investig Drugs 2019 May;28(5):421-433. Epub 2019 Apr 13 doi: 10.1080/13543784.2019.1596258. PMID: 30907163

Therapy

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B
Blood 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. PMID: 38096365
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.
Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME
Clin Cancer Res 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221
Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H, Rafae A, Masood A, Wahab A, Sana MK, Ansar I, Neupane K, Umar A, Ehsan A, Hashmi H
Clin Lymphoma Myeloma Leuk 2022 May;22(5):e285-e292. Epub 2021 Nov 1 doi: 10.1016/j.clml.2021.10.014. PMID: 34879994
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schönland S, Fonseca R, Wong S, Kapoor P
Blood Cancer J 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w. PMID: 33431806Free PMC Article
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Smolewski P, Rydygier D
Expert Opin Investig Drugs 2019 May;28(5):421-433. Epub 2019 Apr 13 doi: 10.1080/13543784.2019.1596258. PMID: 30907163

Prognosis

Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.
Rieger MJ, Pabst T, Jeker B, Paul P, Bergamini F, Bühler MM, Condoluci A, Flammer AJ, Rossi D, Stussi G, Gerber B, Schwotzer R
Ann Hematol 2024 Oct;103(10):4163-4170. Epub 2024 Jul 17 doi: 10.1007/s00277-024-05901-x. PMID: 39020041Free PMC Article
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC
Eur J Haematol 2021 Feb;106(2):184-195. Epub 2020 Nov 9 doi: 10.1111/ejh.13535. PMID: 33090552
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Milani P, Sharpley F, Schönland SO, Basset M, Mahmood S, Nuvolone M, Kimmich C, Foli A, Sachchithanantham S, Merlini G, Wechalekar A, Palladini G, Hegenbart U
Amyloid 2020 Dec;27(4):231-236. Epub 2020 May 25 doi: 10.1080/13506129.2020.1767566. PMID: 32449385
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD
Amyloid 2020 Sep;27(3):200-205. Epub 2020 May 15 doi: 10.1080/13506129.2020.1765768. PMID: 32408823
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Lecumberri R, Krsnik I, Askari E, Sirvent M, González-Pérez MS, Escalante F, Pradillo V, Tamariz LE, Cánovas V, Alegre A, Gironella M, González-García ME, Infante MS, Lakhwani S, Martínez-Bilbao C, Dourdil V, Ramírez-Payer Á, Sarrá J, Cibeira MT
Amyloid 2020 Sep;27(3):163-167. Epub 2020 Feb 28 doi: 10.1080/13506129.2020.1730791. PMID: 32106714

Clinical prediction guides

Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.
Rieger MJ, Pabst T, Jeker B, Paul P, Bergamini F, Bühler MM, Condoluci A, Flammer AJ, Rossi D, Stussi G, Gerber B, Schwotzer R
Ann Hematol 2024 Oct;103(10):4163-4170. Epub 2024 Jul 17 doi: 10.1007/s00277-024-05901-x. PMID: 39020041Free PMC Article
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E
Am J Hematol 2023 May;98(5):720-729. Epub 2023 Feb 14 doi: 10.1002/ajh.26866. PMID: 36708469
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.
Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME
Clin Cancer Res 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC
Eur J Haematol 2021 Feb;106(2):184-195. Epub 2020 Nov 9 doi: 10.1111/ejh.13535. PMID: 33090552
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD
Amyloid 2020 Sep;27(3):200-205. Epub 2020 May 15 doi: 10.1080/13506129.2020.1765768. PMID: 32408823

Recent systematic reviews

Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H, Rafae A, Masood A, Wahab A, Sana MK, Ansar I, Neupane K, Umar A, Ehsan A, Hashmi H
Clin Lymphoma Myeloma Leuk 2022 May;22(5):e285-e292. Epub 2021 Nov 1 doi: 10.1016/j.clml.2021.10.014. PMID: 34879994
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC
Eur J Haematol 2021 Feb;106(2):184-195. Epub 2020 Nov 9 doi: 10.1111/ejh.13535. PMID: 33090552

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...